Skip to main content
SpringerLink
Log in

Classification of Vaccines

  • Chapter
  • First Online:
Subunit Vaccine Delivery

Part of the book series: Advances in Delivery Science and Technology ((ADST))

Abstract

Vaccination has contributed significantly to improving public health by reducing the mortality caused by a number of infectious diseases. Thanks to extensive childhood vaccination programs during the past century, the incidences of diseases such as smallpox, diphtheria, tetanus, polio, mumps, rubella, measles, meningitis, and pneumococcus have decreased dramatically. However, infectious diseases are still the major cause of death worldwide, and these cannot be prevented by vaccines yet due to a number of factors such as incomplete vaccine coverage, antigenic drift/shift, and lack of efficient vaccines, which call for continued progress in the field towards development of novel vaccines. The first vaccines used were live, attenuated, or inactivated whole organism vaccines. Due to safety reasons, new generation vaccines are usually of the subunit vaccine type, which are based on highly purified recombinant antigens. The downside of the improved safety is reduced immunogenicity, as compared to the whole organisms, requiring the use of adjuvants to stimulate sufficient immunity. Adjuvants are often particulate in nature and may contain pathogen-associated molecular patterns (PAMPs) that stimulate the immune system via pattern-recognition receptors (PRRs). Subunit vaccines thus constitute highly complex formulations, which require extensive pharmaceutical analysis and quality control to ensure optimal safety, efficacy, and stability. This chapter provides an introduction to vaccinology and the classification of vaccines, which will provide the basis for understanding new approaches and technologies to deliver and formulate human vaccines including the use of new adjuvants and alternative administration routes, which are presented throughout this book.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol 4:114

    Article  PubMed Central  PubMed  Google Scholar 

  • Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 4:e4384

    Article  PubMed Central  PubMed  Google Scholar 

  • Bins AD, Van Den Berg JH, Oosterhuis K, Haanen JB (2013) Recent advances towards the clinical application of DNA vaccines. Neth J Med 71:109–117

    CAS  PubMed  Google Scholar 

  • Bloom DE, Canning D, Weston M (2005) The value of vaccination. World Economics 6:15

    Google Scholar 

  • Bovier PA (2008) Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther 8:1177–1185

    Article  CAS  PubMed  Google Scholar 

  • Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65:3231–3240

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Clem AS (2011) Fundamentals of vaccine immunology. J Glob Infect Dis 3:73–78

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Clements CJ, Griffiths E (2002) The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl 3):S24–S33

    Article  PubMed  Google Scholar 

  • De Bruijn IA, Nauta J, Gerez L, Palache AM (2006) The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 24:6629–6631

    Article  PubMed  Google Scholar 

  • Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16:3149–3157

    Article  CAS  PubMed  Google Scholar 

  • Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196

    Article  CAS  PubMed  Google Scholar 

  • Ehreth J (2003) The global value of vaccination. Vaccine 21:596–600

    Article  PubMed  Google Scholar 

  • Foged C (2011) Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv 2:1057–1077

    Article  CAS  PubMed  Google Scholar 

  • Galli G, Hancock K, Hoschler K, Devos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I (2009a) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106:7962–7967

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F (2009b) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 106:3877–3882

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Garcon N (2010) Preclinical development of AS04. Methods Mol Biol 626:15–27

    Article  CAS  PubMed  Google Scholar 

  • Garcon N, Chomez P, Van Mechelen M (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6:723–739

    Article  CAS  PubMed  Google Scholar 

  • Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N (2010) Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 64:432–438

    Article  CAS  PubMed  Google Scholar 

  • Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76:141–165

    Article  CAS  PubMed  Google Scholar 

  • Glenny AT, Pope CG, Waddington H, Wallace U (1926) Immunological notes. XVII–XXIV. J Pathol Bacteriol 29:31–40

    Article  CAS  Google Scholar 

  • Gluck R, Metcalfe IC (2002) New technology platforms in the development of vaccines for the future. Vaccine 20(Suppl 5):B10–B16

    Article  CAS  PubMed  Google Scholar 

  • Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505–517

    Article  CAS  PubMed  Google Scholar 

  • Huang DB, Wu JJ, Tyring SK (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect 49:179–209

    Article  PubMed  Google Scholar 

  • Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135–145

    Article  CAS  PubMed  Google Scholar 

  • Mortellaro A, Ricciardi-Castagnoli P (2011) From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease. Immunol Cell Biol 89:332–339

    Article  PubMed  Google Scholar 

  • O’Hagan DT, De Gregorio E (2009) The path to a successful vaccine adjuvant—‘the long and winding road’. Drug Discov Today 14:541–551

    Article  PubMed  Google Scholar 

  • O’Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727–735

    Article  PubMed  Google Scholar 

  • O’Hagan DT (2001) Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1:273–286

    Article  PubMed  Google Scholar 

  • Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680

    Article  CAS  PubMed  Google Scholar 

  • Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25:1361–1366

    Article  CAS  PubMed  Google Scholar 

  • Ravanfar P, Satyaprakash A, Creed R, Mendoza N (2009) Existing antiviral vaccines. Dermatol Ther 22:110–128

    Article  PubMed  Google Scholar 

  • Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23–32

    Article  CAS  PubMed  Google Scholar 

  • Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597–1608

    Article  CAS  PubMed  Google Scholar 

  • Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18:21–25

    Google Scholar 

  • Robinson HL, Amara RR (2005) T cell vaccines for microbial infections. Nat Med 11:S25–S32

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez PC, Rodriguez G, Gonzalez G, Lage A (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 12:17–23

    PubMed  Google Scholar 

  • Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28:1740–1745

    Article  CAS  PubMed  Google Scholar 

  • Romanowski B, De Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374:1975–1985

    Article  PubMed  Google Scholar 

  • Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10):K53–K61

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schultze V, D’agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209–3222

    Article  CAS  PubMed  Google Scholar 

  • Schwarz TF (2009) Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 26:983–998

    Article  PubMed  Google Scholar 

  • Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2:e23803

    Article  PubMed Central  PubMed  Google Scholar 

  • Walker WT, Faust SN (2010) Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 9:1385–1398

    Article  CAS  PubMed  Google Scholar 

  • Wellington K, Goa KL (2003) Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 63:2107–2126

    Article  PubMed  Google Scholar 

  • WHO (2004) BCG vaccine. WHO position paper. Wkly Epidemiol Rec 79:27–38

    Google Scholar 

  • WHO (2012) Summary of WHO position papers—recommendation for routine immunization in: immunization, vaccines and biologicals. World Health Organization, Geneva

    Google Scholar 

  • WHO Fact Sheet 104. (2012). http://www.who.int/mediacentre/factsheets/fs104/en/

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen Ø, Denmark

    Rie S. Kallerup & Camilla Foged

Authors
  1. Rie S. Kallerup
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camilla Foged
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rie S. Kallerup .

Editor information

Editors and Affiliations

  1. Department of Pharmacy, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark

    Camilla Foged

  2. University of Copenhagen, Copenhagen, Denmark

    Thomas Rades

  3. Pharmacy School, Aston University, School of Life and Health Sciences, Birmingham, United Kingdom

    Yvonne Perrie

  4. Division of Health Sciences, University of Otago, School of Pharmacy, Dunedin, New Zealand

    Sarah Hook

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kallerup, R.S., Foged, C. (2015). Classification of Vaccines. In: Foged, C., Rades, T., Perrie, Y., Hook, S. (eds) Subunit Vaccine Delivery. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1417-3_2

Download citation

Publish with us

Policies and ethics

Search

Navigation